Tubulis
https://tubulis.comDeveloper of chemotherapeutic drugs designed to fight against cancer and chronic diseases.
Summary
Industry
Insights
Tubulis has notable potential in developing chemotherapeutic drugs targeting cancer and chronic diseases. Based in Munich, the company focuses on innovative drug development to address limitations of existing chemotherapy treatments. Using a B2B model, Tubulis partners with larger pharmaceutical companies and healthcare providers, channeling their technological advancements into the market. Supported by investors such as Nextech Invest and EQT Life Sciences, Tubulis enjoys robust financial backing and industry credibility. Their specialized approach aims to offer more effective and targeted treatments, positioning them competitively against traditional chemotherapy options and potentially accelerating progress in combating serious health conditions.
Investors
Nextech Invest Series B
EQT Life Sciences Series B
BioMedPartners Series B
Andera Partners Series B
High-Tech Gründerfonds Unknown
High-Tech Gründerfonds Unknown
Bayern Kapital Unknown
Coparion Unknown
Seventure Partners Unknown
Full Company Profile
- Access details of the company management, and other intelligence on this company by registering for Seedtable